U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053891) titled 'LUPKYNIS Drug-use Results Survey' on June 27.
Brief Summary: The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Study Start Date: July 01
Study Type: OBSERVATIONAL
Condition:
Lupus Nephritis
Intervention:
DRUG: Voclosporin (LUPKYNIS)
In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corti...